Abstract
Nephropathic cystinosis is an autosomal recessive lysosomal storage disorder in which intracellular cystine accumulates due to impaired transport out of lysosomes. The clinical manifestations include renal tubular Fanconi syndrome in the 1st year of life, with hypophosphatemic rickets, hypokalemia, polyuria, dehydration and acidosis, growth retardation, hypothyroidism, photophobia, renal glomerular deterioration by 10 years of age, and late complications such as myopathy, pancreatic insufficiency, and retinal blindnesss. The cystinosis gene, CTNS, codes for cystinosin, a 367 amino acid protein with seven transmembrane domains. More than 50 CTNS mutations have been identified, but approximately 50% of Northern European patients have a 57257-bp deletion which removes the first nine exons of CTNS. The mainstay of cystinosis therapy is oral cysteamine (Cystagon). This aminothiol can lower intracellular cystine content by 95%, and has proven efficacy in delaying renal glomerular deterioration, enhancing growth, preventing hypothyroidism, and lowering muscle cystine content. Its early and diligent use is critical; in one study, for every month of treatment prior to 3 years of age, 14 months’ worth of later renal function were preserved. Several examples of individual patients treated early and having preserved renal function and normal growth are available. Newborn screening using a chip containing cDNA to detect common CTNS mutations may allow diagnosis and treatment in the first weeks of life. Conclusion: Early diagnosis and treatment of nephropathic cystinosis can change the course of this disease.
Similar content being viewed by others
References
Anikster Y, Lucero C, Touchman JW, Huizing M, McDowell G, Shotelersuk V, Green ED, Gahl WA (1999) Identification and detection of the common 65-kb deletion breakpoint in the nephropathic cystinosis gene (CTNS). Mol Genet Metab 66: 111–116
Anikster Y, Lacbawan F, Brantly M, Gochuico BL, Avila NA, Travis W, Gahl WA (2001) Pulmonary dysfunction in adults with nephropathic cystinosis. Chest 119: 394–401
Gahl WA (1986) Cystinosis coming of age. Adv Pediatr 33: 95–126
Gahl WA, Kaiser-Kupfer MI (1987) Complications of nephropathic cystinosis after renal failure. Pediatr Nephrol 1: 260–268
Gahl WA, Bashan N, Tietze F, Bernardini I, Schulman JD (1982) Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. Science 217: 1263–1265
Gahl WA, Tietze F, Bashan N, Bernardini I, Schulman JD (1983) Characteristics of cystine counter-transport in normal and cystinotic lysosome-rich leucocyte granular fraction. Biochem J 216: 393–400
Gahl WA, Tietze F, Butler JDB, Schulman JD (1985) Cysteamine depletes lysosomal cystine by the mechanism of disulfide interchange. Biochem J 228: 545–550
Gahl WA, Reed GF, Thoene JG, Schulman JD, Rizzo WB, Jonas AJ, Denman DW, Schlesselman JJ, Corden BJ, Schneider JA (1987) Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 316: 971–977
Gahl WA, Charnas L, Markello TC, Bernardini I, Ishak KG, Dalakas MC (1992) Parenchymal organ cystine depletion with long term cysteamine therapy. Biochem Med Metab Biol 48: 275–285
Gahl WA, Bernardini I, Dalakas M, Markello T, Krasnewich D, Charnas L (1993) Muscle carnitine repletion by long-term carnitine supplementation in nephropathic cystinosis. Pediatr Res 34: 115–119
Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI (2000) Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab 71: 100–121
Gahl WA, Thoene JG, Schneider JA (2001) Disorders of lysosomal membrane transport. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3763–3797
Kaiser-Kupfer MI, Fujikawa L, Kuwabara T, Gahl WA (1987) Removal of corneal crystals by topical cysteamine in nephropathic cystinosis. N Engl J Med 316: 775–779
Kaiser-Kupfer MI, Gazzo MA, Datiles MB, Caruso RC, Kuehl EM, Gahl WA (1990) A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis. Arch Ophthalmol 108: 689–693
Kalatzis V, Cherqui S, Antignac C, Gasnier B (2001) Cystinosin, the protein defective in cystinosis, is a H+-driven lysosomal cystine transporter. EMBO 20: 5940–5949
Kimonis VE, Troendle J, Yang ML, Rose SR, Markello TC, Gahl WA (1995) Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J Clin Endocrinol Metab 80: 3257–3261
Markello TC, Bernardini IM, Gahl WA (1993) Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 328: 1157–1162
Pisoni RL, Thoene JG, Christensen HN (1985) Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts. J Biol Chem 260: 4791–4798
Shotelersuk V, Larson D, Anikster Y, McDowell G, Lemons R, Bernardini I, Guo J, Thoene J, Gahl W (1998) CTNS mutations in an American-based population of cystinosis patients. Am J Hum Genet 63: 1352–1362
Theodoropoulos DS, Krasnewich D, Kaiser-Kupfer MI, Gahl WA (1993) Classical nephropathic cystinosis as an adult disease. JAMA 270: 2200–2204
Thoene J, Oshima R, Crawhall J, Olson D, Schneider J (1976) Cystinosis: intracellular cystine depletion by aminothiols in vitro and vivo. J Clin Invest 58: 180–189
Touchman JW, Anikster Y, Dietrich NL, Braden VV, McDowell G, Shotelersuk V, McPherson JD, Bouffard GG, Beckstrom-Sternberg SM, Gahl WA, Green ED (2000) The genomic region encompassing the nephropathic cystinosis gene (CTNS): complete sequencing of a 200-kb segment and discovery of a novel gene within the common cystinosis-causing deletion. Genome Res 10: 165–173
Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, Callen DF, Gribouval O, Broyer M, Bates GP, van’t Hoff W, Antignac C (1998) A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet 18: 319–324
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gahl, W.A. Early oral cysteamine therapy for nephropathic cystinosis. Eur J Pediatr 162 (Suppl 1), S38–S41 (2003). https://doi.org/10.1007/s00431-003-1349-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-003-1349-x